nach oben

International Journal of Clinical Oncology

Erschienen in:

17.03.2020 | Original Article

Prognostic significance of β2-adrenergic receptor expression in patients with surgically resected colorectal cancer

verfasst von: Hiroomi Ogawa, Kyoichi Kaira, Yoko Motegi, Takehiko Yokobori, Takahiro Takada, Ryuji Kato, Katsuya Osone, Ryo Takahashi, Kunihiko Suga, Naoya Ozawa, Chika Katayama, Tetsunari Oyama, Akira Shimizu, Takashi Yao, Takayuki Asao, Hiroshi Saeki, Ken Shirabe

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The β2-adrenergic receptor (β2AR) is highly expressed in various human cancers. The prognostic significance of its expression in patients with colorectal cancer (CRC) remains unclear. The aim of this study was to assess the prognostic role of β2AR expression in patients with surgically resected CRC.

Methods

One hundred and forty-seven patients with surgically resected CRC were examined using immunohistochemistry. The expression of β2AR was assessed in the specimens of resected primary tumors.

Results

β2AR was expressed in 52.3% of the patients’ tumors. β2AR expression was significantly associated with T factor, N factor, and tumor cell proliferation (Ki-67 labeling index). Univariate analysis demonstrated that T factor, N factor, tumor stage, lymphatic permeation, vascular invasion, perineural invasion, β2AR expression, and Ki-67 labeling index were significant prognostic factors for worse disease-free survival (DFS); all but T factor were also significant predictors for worse overall survival (OS). Multivariate analysis confirmed that expression of β2AR was a significant prognostic marker for predicting worse DFS and OS.

Conclusion

β2AR expression was identified as a significant independent prognostic factor in patients with surgically resected CRC.

Matsuda T, Yamashita K, Hasegawa H et al (2018) Recent updates in the surgical treatment of colorectal cancer. Ann Gastroenterol Surg 2:129–136CrossRefPubMedPubMedCentral

Kakeji Y, Takahashi A, Udagawa H et al (2017) Surgical outcomes in gastroenterological surgery in Japan: report of national clinical database 2011–2016. Ann Gastroenterol Surg 2:37–54CrossRefPubMedPubMedCentral

Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499–508CrossRefPubMed

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMed

Maudsley S, Pierce KL, Zamah AM et al (2000) The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 275:9572–9580CrossRefPubMed

Entschladen F, Drell TL 4th, Lang K et al (2004) Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol 5:254–258CrossRefPubMed

Thaker PH, Han LY, Kamat AA et al (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12:939–944CrossRefPubMed

Chen D, Xing W, Hong J et al (2012) The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection. Ann Surg Oncol 19:3556–3565CrossRefPubMed

Yazawa T, Kaira K, Shimizu A et al (2016) Prognostic significance of β2-adrenergic receptor expression in non-small cell lung cancer. Am J Transl Res 8:5059–5070PubMedPubMedCentral

10.

Takahashi K, Kaira K, Shimizu A et al (2016) Clinical significance of β2-adrenergic receptor expression in patients with surgically resected gastric adenocarcinoma. Tumor Biol 37:13885–13892CrossRef

11.

Shimizu A, Kaira K, Mori K et al (2016) Prognostic significance of β2-adrenergic receptor expression in malignant melanoma. Tumor Biol 37:5971–5978CrossRef

12.

Melhem-Bertrandt A, Chavez-Macgregor M, Lei X et al (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29:2645–2652CrossRefPubMedPubMedCentral

13.

Barron TI, Connolly RM, Sharp L et al (2011) Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 29:2635–2644CrossRefPubMed

14.

Shang ZJ, Liu K, Liang DF (2009) Expression of beta2-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med 38:371–376CrossRefPubMed

15.

Kaira K, Kamiyoshihara M, Kawashima O et al (2019) Prognostic impact of β2-adrenergic receptor expression in surgically resected pulmonary pleomorphic carcinoma. Anticancer Res 39:395–403CrossRefPubMed

16.

Ciurea RN, Rogoveanu I, Pirici D et al (2017) B2 adrenergic receptors and morphological changes of the enteric nervous system in colorectal adenocarcinoma. World J Gastroenterol 23:1250–1261CrossRefPubMedPubMedCentral

17.

Bravo-Calderón DM, Oliveira DT, Marana AN, Nonogaki S, Carvalho AL, Kowalski LP (2010) Prognostic significance of beta-2 adrenergic receptor in oral squamous cell carcinoma. Cancer Biomark 10:51–59CrossRef

18.

De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, Marchionni N, Geppetti P (2011) Treatment with beta-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 171:779–781PubMed

19.

Lemeshow S, Sorensen HT, Phillips G et al (2011) beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 20:2273–2279CrossRefPubMedPubMedCentral

20.

Chisholm KM, Chang KW, Truong MT et al (2012) β-adrenergic receptor expression in vascular tumors. Mod Pathol 25:1446–1451CrossRefPubMed

21.

Wang F, Liu H, Wang F et al (2018) Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells. Mol Med Rep 17:5213–5221PubMedPubMedCentral

22.

Iseri OD, Sahin FI, Teizi YK et al (2014) beta-adrenergic antagonists reduce cancer cell proliferation, invasion and migration. Pharm Biol 52:1374–1381CrossRefPubMed

23.

Watanabe T, Muro K, Ajioka Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1–34CrossRefPubMed

Titel: Prognostic significance of β2-adrenergic receptor expression in patients with surgically resected colorectal cancer
verfasst von: Hiroomi Ogawa
Kyoichi Kaira
Yoko Motegi
Takehiko Yokobori
Takahiro Takada
Ryuji Kato
Katsuya Osone
Ryo Takahashi
Kunihiko Suga
Naoya Ozawa
Chika Katayama
Tetsunari Oyama
Akira Shimizu
Takashi Yao
Takayuki Asao
Hiroshi Saeki
Ken Shirabe
Publikationsdatum: 17.03.2020
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 6/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-020-01645-6

Springer Medizin

Prognostic significance of β2-adrenergic receptor expression in patients with surgically resected colorectal cancer